Search for a command to run...
<h3>Background and Importance</h3> Migraine is one of the main pathologies in hospital pharmaceutical expenditure. Due to the high cost of these drugs, the increase in diagnoses, and the marketing of new therapeutic alternatives, hospital pharmacists must play a very important role in creating protocols that guarantee budgetary sustainability. <h3>Aim and Objectives</h3> Analyse the degree of compliance with the migraine protocol established in a hospital following the introduction of the oral anti-migraine drug Rimegepant and the economic impact of implementing the protocol. <h3>Material and Methods</h3> All migraine medication prescriptions between March 2023 and March 2025 were retrospectively analysed and a comparative study was conducted between the periods with and without the protocol (April 2023 to March 2024 versus April 2024 to March 2025). The protocol established the first-line use of rimegepant, followed by eptinezumab, fremanezumab, erenumab, and galcanezumab. <h3>Results</h3> During the period without a protocol, 26 treatments were initiated(8 with eptinezumab, 6 with erenumab, 9 with fremanezumab, and 3 with galcanezumab). Subsequently, with the protocol in place, treatment was initiated in 30 patients (20 with rimegepant, 5 with eptinezumab, 3 with fremanezumab, and 2 with galcanezumab). In terms of treatment changes after implementation, there were 8 line changes to rimegepant: 5 changed from erenumab, 2 from galcanezumab, and 1 from galcanezumab. There were 11 line changes to eptinezumab: 5 from erenumab, 4 from galcanezumab, and 2 from fremanezumab. Theoverall degree of compliance with the protocol was 66.67%, and the savings, the cost of choosing thebest option, have been €20,480 since the implementation of theprotocol in the study period. <h3>Conclusion and Relevance</h3> Our results show a high degree of compliance with the protocol as well as significant economic savings based on its implementation. In addition, the conditions of many patients already undergoing treatment improved when switching from subcutaneous to oral treatment. <h3>Conflict of Interest</h3> No conflict of interest